Kidney Cancer

Centering discussion on the KCRS 2023 annual meeting, experts in renal cell carcinoma elucidate data from the CLEAR and TRAVERSE studies in clear cell disease.

Experts discuss recent data on a triplet combination therapy for patients with advanced non-clear cell renal cell carcinoma.

Drs Robert Motzer and Moshe Ornstein discuss the results of the KEYNOTE-B61 study in patients with non-clear cell renal cell carcinoma.

The panel highlights novel agents under investigation for the treatment of clear cell renal cell carcinoma.

Moshe Ornstein, MD, reviews the design and efficacy and safety data from the phase 3 CONTACT-03 study in metastatic renal cell carcinoma.

The investigational T-cell therapy IVS-3001 is currently under evaluation as part of a phase 1/2 trial in patients with advanced or metastatic solid tumors that are HLA-G positive.

Dr Moshe Ornstein details the adverse events seen with IO/TKI combination regimens in patients with advanced renal cell carcinoma and the best strategies for management.

Experts discuss the optimal treatment of patients with renal cell carcinoma and brain, bone, or lung metastases.

Lenvatinib in combination with pembrolizumab appears to raise no new safety signals in patients with advanced clear cell renal cell carcinoma after 4 years of follow-up in the phase 3 CLEAR study.

According to Thomas E. Hutson, DO, PharmD, FACP, 4-year follow-up data from the phase 3 CLEAR study confirm the maintained benefits of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.

Rana R. McKay, MD discusses presentations of interest that were presented at the 2023 Kidney Cancer Research Summit, including a discussion on how PET imaging may identify which patients with renal cell carcinoma may respond to immunotherapy.

Moshe Ornstein, MD, explains how he selects a frontline IO/TKI combination regimen for a patient with advanced renal cell carcinoma.

Dr Brian Rini shares his view on the data comparing IO/TKI and IO/IO combination regimens for the treatment of advanced renal cell carcinoma.

A better understanding of tumor biology may be necessary for identifying novel non-immunotherapy–based therapeutic strategies for patients with renal cell carcinoma, according to Rana R. McKay, MD.

Probiotics and other agents targeting fatty acid oxidation are also under evaluation as treatment options for patients with renal cell carcinoma, according to Rana R. McKay, MD.

Patients with metastatic renal cell carcinoma, and those who have been pretreated with immune checkpoint inhibitors and are naive, saw a benefit with lenvatinib plus pembrolizumab.

Eddy Saad, MD, explained how responses to immune checkpoint inhibitors can be elicited in patients with metastatic renal cell carcinoma.

The phase 2 ORCHID trial met the respecified end point of Simon stage 1 design for patients with BAP1-mutated renal cell carcinoma.

Better biology is needed to accurately determine risk stratification features in patients with clear cell renal cell carcinoma.

Robert J. Motzer, MD, reviews the need for increased studies on the use of immunotherapy in later-line settings for advanced renal cell carcinoma.

In patients with metastatic renal cell carcinoma, neoadjuvant immunotherapy–based combinations yielded reductions in tumor size and pathologic necrosis at the time of cytoreductive nephrectomy.

Clear cell renal cell carcinoma is driven by a metabolic switch that decreases VHL and increases ATP, according to an expert from Vanderbilt University Medical Center.

Findings from the phase 3 KEYNOTE-564 trial support adjuvant pembrolizumab following nephrectomy as a standard-of-care treatment for patients with clear cell renal cell carcinoma.

The improvements occur regardless of PD-L1 status among patients receiving lenvatinib plus pembrolizumab for advanced renal cell carcinoma in the phase 3 CLEAR study.

Using a laser ablation system, imaging mass cytometry is designed to measure over 40 metal isotopes in a tumor sample to identify how immune cells in clear cell renal cell carcinoma are organized.

Brian Rini, MD, reviews data from the 5-year analysis of the KEYNOTE-426 trial in advanced clear cell renal cell carcinoma.

Robert Motzer, MD, presents the overall survival analysis data from the 4-year follow-up of the CLEAR study in patients with advanced renal cell carcinoma.

Experts present and discuss new findings from the CheckMate 9ER trial, evaluating nivolumab plus cabozantinib vs sunitinib in renal cell carcinoma.

A panel of experts, a patient, and her caregiver discuss her renal cell carcinoma diagnosis, the prevalent treatment options, and optimal strategies for patient education.

Syed Arslan Shehzad Shah, MD, and colleagues present findings from a broad investigation into this rare neoplasm of the kidney, including data on patient demographics and mean survival.